Privo is excited to share the recent Forbes article titled, “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems” written by one of our manuscript authors, Alex Zhavoronkov, PhD that highlights our nanoengineered PRV Platform. Click the below to access the fill Forbes article.
Peabody, MA -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy... read more
Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was rated... read more
Privo Technologies Inc., a pioneering biopharmaceutical company known for its innovative approach to drug delivery and cancer treatment, is proud... read more
Privo Technologies, Inc., a clinical-stage biopharmaceutical company pioneering nanotechnology-based cancer therapies, is thrilled to announce the activation of multiple premier... read more
PEABODY, Mass., October 22, 2021 --Privo Technologies, Inc. ("Privo"), announced today the positive results of their Phase 1/2 clinical trial examining... read more
Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future oral... read more
Privo Technologies is honored to receive a Phase 2 award for $2M from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program.
read more
- © UX Strategy & Digital Branding
